Figure 3
From: EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma
In vitro assays of Huh7 and HepG2 cells treated with GSK126 or UNC1999. (A) GSK126 and UNC1999 inhibit S-Adenosyl methionine competitively. (B) Cell growth inhibition of HCC cells treated with GSK126 and UNC1999 (repeated measures ANOVA, *p < 0.05, **p < 0.01). (C) Quantification of apoptotic cells treated with GSK126 and UNC1999 for 48 h based on percentages of CASP3-positive cells by immunostaining (Student’s t test, *p < 0.05, **p < 0.01). (D) Western blot analysis for EZH1, EZH2 and H3K27me3 after treatment of HCC cells with a range of concentrations of GSK126 and UNC1999 for 48 or 96 h. RI was shown as the means of three independent experiments.
